{"entity":{"type":"insider","cik":"0001286397","url":"/insider/0001286397","json_url":"/insider/0001286397.json","name":"CARTHY MARK","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":13,"n_filings":7,"first":"2004-06-04","last":"2006-10-20","span_basis":"filed_date"},"name_variants":[{"name":"CARTHY MARK","source":"filing","n_filings":7,"first_seen":"2004-06-04","last_seen":"2006-10-20"}],"transactions":[{"id":4179863,"accession":"0001012975-06-000417","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-06-000417","line_url":"/filing/0001012975-06-000417","is_derivative":false,"issuer_cik":"0001140484","issuer_name":"Cyberkinetics Neurotechnology Systems, Inc.","issuer_ticker":"CYKN","issuer_name_source":null,"issuer_url":"/issuer/0001140484","owner_cik":null,"owner_name":"WALTON ALAN G; BARNES JEFFREY T; MRNA FUND II LP; CARTHY MARK; OXFORD BIOSCIENCE PARTNERS IV LP; LYTTON MICHAEL; OBP MANAGEMENT IV LP; FLEMING JONATHAN","owner_display_name":"WALTON ALAN G","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":833334.0,"shares_display":"833,334","price_per_share":1.2,"price_display":"1.20","price_state":"stated","total_value":1000000.8,"total_display":"1,000,000.80","total_whole":"1,000,001","shares_owned_after":10436017.0,"shares_owned_after_display":"10,436,017","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-10-18","filed_date":"2006-10-20","scope":"insider","n_lines":2},{"id":3688240,"accession":"0001012975-06-000412","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-06-000412","line_url":"/filing/0001012975-06-000412","is_derivative":false,"issuer_cik":"0001140484","issuer_name":"Trubion Pharmaceuticals, Inc","issuer_ticker":"TRBN","issuer_name_source":null,"issuer_url":"/issuer/0001140484","owner_cik":null,"owner_name":"OXFORD BIOSCIENCE PARTNERS IV LP; WALTON ALAN G; OBP MANAGEMENT IV LP; CARTHY MARK; FLEMING JONATHAN; LYTTON MICHAEL; BARNES JEFFREY T; MRNA FUND II LP","owner_display_name":"OXFORD BIOSCIENCE PARTNERS IV LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":41614.0,"shares_display":"41,614","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":540982.0,"total_display":"540,982.00","total_whole":"540,982","shares_owned_after":41201.0,"shares_owned_after_display":"41,201","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-10-17","filed_date":"2006-10-19","scope":"insider","n_lines":2},{"id":1624147,"accession":"0001012975-05-000312","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-05-000312","line_url":"/filing/0001012975-05-000312","is_derivative":false,"issuer_cik":"0001140484","issuer_name":"Cyberkinetics Neurotechnology Systems, Inc.","issuer_ticker":"CYKN","issuer_name_source":null,"issuer_url":"/issuer/0001140484","owner_cik":null,"owner_name":"OXFORD BIOSCIENCE PARTNERS IV LP; OBP MANAGEMENT IV LP; CARTHY MARK; MRNA FUND II LP; FLEMING JONATHAN; LYTTON MICHAEL; BARNES JEFFREY T; WALTON ALAN G","owner_display_name":"OXFORD BIOSCIENCE PARTNERS IV LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500000.0,"shares_display":"2,500,000","price_per_share":1.2,"price_display":"1.20","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":9610961.0,"shares_owned_after_display":"9,610,961","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-09-26","filed_date":"2005-09-28","scope":"insider","n_lines":2},{"id":1337819,"accession":"0001140484-05-000017","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140484-05-000017","line_url":"/filing/0001140484-05-000017","is_derivative":false,"issuer_cik":"0000913275","issuer_name":"Solexa, Inc.","issuer_ticker":"SLXA","issuer_name_source":null,"issuer_url":"/issuer/0000913275","owner_cik":null,"owner_name":"MRNA FUND II LP; OXFORD BIOSCIENCE PARTNERS IV LP; OBP MANAGEMENT IV LP; LYTTON MICHAEL; FLEMING JONATHAN; BARNES JEFFREY T; CARTHY MARK; WALTON ALAN G","owner_display_name":"MRNA FUND II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":550000.0,"shares_display":"550,000","price_per_share":4.0,"price_display":"4.00","price_state":"stated","total_value":2200000.0,"total_display":"2,200,000.00","total_whole":"2,200,000","shares_owned_after":3013522.0,"shares_owned_after_display":"3,013,522","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-07-12","filed_date":"2005-07-14","scope":"insider","n_lines":2},{"id":1297194,"accession":"0001140484-05-000010","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140484-05-000010","line_url":"/filing/0001140484-05-000010#line-1","is_derivative":false,"issuer_cik":"0001070494","issuer_name":"ACADIA PHARMACEUTICALS INC","issuer_ticker":"ACAD","issuer_name_source":null,"issuer_url":"/issuer/0001070494","owner_cik":null,"owner_name":"OXFORD BIOSCIENCE PARTNERS IV LP; WALTON ALAN G; OBP MANAGEMENT IV LP; CARTHY MARK; FLEMING JONATHAN; LYTTON MICHAEL; BARNES JEFFREY T","owner_display_name":"OXFORD BIOSCIENCE PARTNERS IV LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":586402.0,"shares_display":"586,402","price_per_share":6.8213,"price_display":"6.82","price_state":"stated","total_value":4000023.9626,"total_display":"4,000,023.96","total_whole":"4,000,024","shares_owned_after":3160238.0,"shares_owned_after_display":"3,160,238","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-04-20","filed_date":"2005-04-21","scope":"insider"},{"id":539754,"accession":"0001286962-04-000009","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001286962-04-000009","line_url":"/filing/0001286962-04-000009","is_derivative":false,"issuer_cik":"0001140484","issuer_name":"Cyberkinetics Neurotechnology Systems, Inc.","issuer_ticker":"CYKN","issuer_name_source":null,"issuer_url":"/issuer/0001140484","owner_cik":null,"owner_name":"MRNA FUND II LP; WALTON ALAN G; BARNES JEFFREY T; FLEMING JONATHAN; LYTTON MICHAEL; OBP MANAGEMENT IV LP; CARTHY MARK; OXFORD BIOSCIENCE PARTNERS IV LP","owner_display_name":"MRNA FUND II LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":318501.0,"shares_display":"318,501","price_per_share":3.0,"price_display":"3.00","price_state":"stated","total_value":955503.0,"total_display":"955,503.00","total_whole":"955,503","shares_owned_after":7135795.0,"shares_owned_after_display":"7,135,795","ownership_form":"D","is_10b5_1":null,"transaction_date":"2004-11-04","filed_date":"2004-11-08","scope":"insider","n_lines":2},{"id":336430,"accession":"0001179044-04-000119","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001179044-04-000119","line_url":"/filing/0001179044-04-000119","is_derivative":false,"issuer_cik":"0001070494","issuer_name":"ACADIA PHARMACEUTICALS INC","issuer_ticker":"ACAD","issuer_name_source":null,"issuer_url":"/issuer/0001070494","owner_cik":null,"owner_name":"OXFORD BIOSCIENCE PARTNERS IV LP; MRNA FUND II LP; CARTHY MARK; LYTTON MICHAEL; FLEMING JONATHAN; OBP MANAGEMENT IV LP; BARNES JEFFREY T","owner_display_name":"OXFORD BIOSCIENCE PARTNERS IV LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":285000.0,"shares_display":"285,000","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":1995000.0,"total_display":"1,995,000.00","total_whole":"1,995,000","shares_owned_after":2573836.0,"shares_owned_after_display":"2,573,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2004-06-02","filed_date":"2004-06-04","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001180253","name":"Cyberkinetics Neurotechnology Systems, Inc.","url":"/issuer/0001180253","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2004-11-08","last_seen":"2006-10-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001298521","name":"Trubion Pharmaceuticals, Inc","url":"/issuer/0001298521","role":"Ten percent owner","n_filings":1,"first_seen":"2006-10-19","last_seen":"2006-10-19"},{"type":"issuer","type_label":"ISSUER","cik":"0000913275","name":"Solexa, Inc.","url":"/issuer/0000913275","role":"Ten percent owner","n_filings":1,"first_seen":"2005-07-14","last_seen":"2005-07-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001070494","name":"ACADIA PHARMACEUTICALS INC","url":"/issuer/0001070494","role":"Ten percent owner","n_filings":2,"first_seen":"2004-06-04","last_seen":"2005-04-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001286397","retrieved_at":"2026-08-27T02:11:33+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}